Human recombinant ZO-1 fusion protein encompassing amino acids 334-634
Conjugate
FITC
Form
Liquid
Concentration
0.5 mg/ml
Purification
Affinity chromatography
Storage buffer
PBS, pH 7.4, with 1% BSA, 50% glycerol
Preservative
0.1% sodium azide
Storage Conditions
4° C
Tested Applications
Dilution *
ELISA (ELISA)
0.1-1.0 ug/ml
Immunocytochemistry (ICC)
1-10µg/mL
Immunofluorescence (IF)
1-10µg/mL
Western Blot (WB)
1-2 ug/ml
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Background/Target Information
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Many of the tight junction-associated proteins are members of the membrane- associated guanylate kinase (MAGUK) family and include occludin, ZO-1, ZO-2 and ZO-3. These proteins are thought to have both structural and signaling roles, and are characteristically defined by three protein-protein interaction modules: the PDZ domain, the SH3 domain and the guanylate kinase (GuK) domain. ZO-1 forms complexes with either ZO-2 or ZO-3. In addition, these proteins can also associate with claudin, occludin and F-actin, at tight junction stands, where they provide a linkage between the actin cytoskeleton and the tight junction. ZO-1 expression is significantly reduced in many breast cancer lines. ZO-2 and ZO-3 are ubiquitously expressed within epithelial tight junctions, and unlike ZO-1, which is also expressed at cell junctions of cardiac myocytes, ZO-2 is not expressed in nonepithelial tissue.
原厂资料：
注意事项：
For Research Use Only. Not for use in diagnostic procedures.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
